The hypothesis was tested that corticotropin-releasing factor (CRF) is involved in the inhibition of gonadotropin secretion during chronic hyperprolactinemia. Two models of hyperprolactinemia were used, namely inoculation with the prolactin (PRL)-secreting tumor 7315b and implantation of isogenic pituitary glands. Gonadectomized, adrenalectomized male rats received a testosterone capsule and a corticosterone pellet and were inoculated subcutaneously with tumor 7315b. Similar rats without tumor served as controls. The rats were studied 3–4 weeks later while anesthetized with urethane. Plasma testosterone and corticosterone were similar in the two groups of rats. Compared to controls, the tumor-bearing rats had significantly higher plasma levels of PRL (100-fold increase) and adrenocorticotropin (ACTH; 3-fold increase), whereas plasma luteinizing hormone (LH) and follicle-stimulating hormone (FSH) had significantly decreased to 15 and 40%, respectively. CRF release into hypophysial stalk plasma was higher in rats with tumor 7315b than in controls (298 ± 23 vs. 197 ± 28 pg/h), and hypothalamic CRF content had increased from 3.0 ± 0.3 to 4.3 ± 0.3 ng. Male rats received 3 pituitary glands under the kidney capsule. Sham-operated rats served as controls. They were studied 5–7 weeks later while anesthetized with urethane. Compared to controls, pituitary-grafted rats had larger adrenals (49 ± 4 vs. 34 ± 2 mg), higher plasma PRL (156 ± 18 vs. 52 ± 8 ng/ml), ACTH (0.46 ± 0.05 vs. 0.22 ± 0.02 ng/ml) and corticosterone (455 ± 39 vs. 268 ± 14 ng/ml), and lower plasma levels of LH (21 ± 2 vs. 41 ± 6 ng/ml). Plasma FSH and testosterone, and hypothalamic CRF content were similar in both groups of rats. CRF release into hypophysial stalk plasma was somewhat, but not significantly, higher in pituitary-grafted rats than in control rats (102 ± 32 vs. 82 ± 37 pg/h). Thus, both models of chronic hyperprolactinemia seem to activate the hypothalamic-adenohypophysial-adrenal axis. It is suggested that at least part of the action of PRL is due to an activation of CRF-containing neurons, which causes inhibition of hypothalamic LH-releasing hormone secretion and consequently pituitary gonadotropin release.

Keywords:
Corticotropin-releasing factor, Dopamine, Prolactin, ACTH Tumor 7315b, Pituitary transplants, Adrenalectomy, Gonadotropins, Hypothalamus
This content is only available via PDF.
© 1990 S. Karger AG, Basel
1990
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.